News Column

DGAP-News: STRATEC Annual General Meeting: Shareholders elect new Supervisory Board and approve dividend increase

June 18, 2014

DGAP-News: STRATEC Biomedical AG / Key word(s): AGM/EGM STRATEC Annual General Meeting: Shareholders elect new Supervisory Board and approve dividend increase 18.06.2014 / 18:00 --------------------------------------------------------------------- STRATEC Annual General Meeting: Shareholders elect new Supervisory Board and approve dividend increase Birkenfeld, June 18, 2014 At today's Annual General Meeting in Pforzheim, the shareholders of STRATEC Biomedical AG (Frankfurt: SBS; Prime Standard, TecDAX) approved all of the agenda items put to the vote with large majorities in each case. Prof. Dr. Stefanie Remmele, Landshut, Professor for medical engineering at the Hochschule Landshut - University of Applied Sciences, was newly elected to the three-member Supervisory Board and thus succeeds Prof. Dr. Hugo HÄmmerle. The previous Supervisory Board Chairman, Fred K. BrÜckner, and the previous Deputy Supervisory Board Chairman, Wolfgang Wehmeyer, stood for re-election and were once again elected to the supervisory body by the Annual General Meeting. At the subsequent constitutive meeting of the Supervisory Board, Fred K. BrÜckner was once again elected as Chairman. Wolfgang Wehmeyer was re-elected as Deputy Supervisory Board Chairman and as the independent financial expert pursuant to 100 (5) of the German Stock Corporation Act (AktG). STRATEC is distributing a dividend of EUR 0.60 per share to its shareholders for the 2013 financial year (previous year: EUR 0.56). The distribution total amounts to EUR 7.1 million and will be paid to shareholders via their depository banks from June 20, 2014. The dividend has thus been increased for the tenth year in succession since the initiation of dividend payments in 2004. Further information about the Annual General Meeting can be found on the company's website at www.stratec.com/agm. About STRATEC STRATEC Biomedical AG (www.stratec.com) designs and manufactures fully automated analyzer systems for its partners in the fields of clinical diagnostics and biotechnology. These partners market such systems, in general together with their own reagents, as system solutions to laboratories, blood banks and research institutes around the world. The company develops its products on the basis of its own patented technologies. Shares in the company (ISIN: DE0007289001) are traded in the Prime Standard segment of the Frankfurt Stock Exchange and are listed in the TecDAX select index of the German Stock Exchange. Further information can be obtained from: STRATEC Biomedical AG AndrÉ Loy, Corporate Communications Gewerbestr. 37, 75217 Birkenfeld Germany Tel: +49 7082 7916-190 Fax: +49 7082 7916-999 ir@stratec.comwww.stratec.com End of Corporate News --------------------------------------------------------------------- 18.06.2014 Dissemination of a Corporate News, transmitted by DGAP - a company of EQS Group AG. The issuer is solely responsible for the content of this announcement. DGAP's Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.dgap-medientreff.de and www.dgap.de --------------------------------------------------------------------- Language: English Company: STRATEC Biomedical AG Gewerbestr. 37 75217 Birkenfeld Germany Phone: +49 (0)7082 7916 0 Fax: +49 (0)7082 7916 999 E-mail: info@stratec.com Internet: www.stratec.com ISIN: DE0007289001 WKN: 728900 Indices: TecDAX Listed: Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr in Berlin, DÜsseldorf, MÜnchen, Stuttgart End of News DGAP News-Service --------------------------------------------------------------------- 273971 18.06.2014


For more stories on investments and markets, please see HispanicBusiness' Finance Channel



Source: DGAP Corporate News


Story Tools






HispanicBusiness.com Facebook Linkedin Twitter RSS Feed Email Alerts & Newsletters